FLINT, Mich., Dec. 11, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), has hired Chris Luthin to serve its pharmacy benefit manager (PBM) arm as executive vice president of finance, pharmacy benefit management, and integration.
The company announced agreements in November to acquire two PBMs: National Pharmaceutical Services and LDI Integrated Pharmacy Services. Luthin will oversee the integration process, as well as internal and external financial reporting.
"Chris is a seasoned health care leader who will reinforce our focus on PBM services," said Joel Saban, Diplomat president. "Our managed markets strategy will benefit from his impressive track record managing merger integrations."
Luthin has more than 25 years of health care and finance experience. He held executive roles at CVS Caremark for more than two decades, including executive vice president of PBM operations from 2006 to 2010. During his tenure, Luthin led more than 8,000 employees and the integration of three acquired PBMs. He has also held roles at BioScrip, Inc., and Millennium Pharmacy Systems, Inc., now part of PharMerica Corporation.
"Diplomat has built a talented executive team to support its transition to a broader health care company," Luthin said. "By proactively helping partners handle changes in the market, we can empower them to make better pipeline decisions and make the pharmacy benefit more affordable and accessible. I'm proud to be part of this new chapter for the company."
Luthin holds a master's degree in management from the Kellogg School of Management at Northwestern University. He has a Bachelor of Science in accounting from Northern Illinois University.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
Kali Lucas, Public Relations Specialist
810.768.9580 | email@example.com
SOURCE Diplomat Pharmacy, Inc.